Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 13, Issue 4, Pages 451-460Publisher
OXFORD UNIV PRESS
DOI: 10.1017/S1461145709990939
Keywords
D-serine; glycine; N-methylglycine; NMDA; sarcosine; schizophrenia
Funding
- National Science Council (Taiwan) [NSC-95-2314-B-006-118-MY3, NSC-97-2314-B-039-006-MY3, NSC-98-2627-B-039-001]
- National Health Research Institutes (Taiwan) [NHRI-EX-97-9405PI, NHRI-EX-98-9405PI]
- China Medical University (Taiwan) [DMR-98-096]
- Los Angeles Biomedical Research Institute
- National Alliance of Research
Ask authors/readers for more resources
Recent evidence indicates that enhancing N-methyl-D-aspartate (NMDA) neurotransmission with the treatment of NMDA/glycine site agonists, such as D-serine, or a glycine transporter-1 (GlyT-1) antagonist, N-methylglycine (sarcosine), can improve symptoms of schizophrenia. To compare these two novel approaches, 60 patients with chronic schizophrenia were enrolled into a 6-wk double-blind, placebo-controlled trial of add-on treatments at the reported effective dosages (2 g/d). Clinical assessments were conducted every other week. Treatment group x treatment duration interaction analysis by multiple linear regression showed that sarcosine was superior to placebo at all four outcome measures of Positive and Negative Syndrome Scale (PANSS) total (p = 0.005), Scale for the Assessment of Negative Symptoms (SANS) (p =0.021), Quality of Life (QOL) (p =0.025), and Global Assessment of Functioning (GAF) (p= 0.042). However, D-serine did not differ significantly from placebo in any measure. Sarcosine treatment was better than D-serine in effect sizes for all outcome measures. Sarcosine also surpassed placebo in most of the measures of five PANSS factors and five SANS subscales. All treatments were well tolerated. These findings suggest that the GlyT-1 inhibitor is more efficacious than the NMDA/glycine site agonist in treatment for schizophrenia, including life quality and global function, at the dosages tested.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available